Amgen will buy Micromet for $1.16 billion

01/26/2012 | Genetic Engineering & Biotechnology News

Amgen's acquisition of Micromet for $11 a share was approved by the boards of both companies. The cash transaction, worth about $1.16 billion, gives Amgen access to Micromet's antibody technology Bispecific T-cell Engager and its blood cancer drug candidate blinatumomab.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC